Anticoagulant overdoseMANAGEMENT

TOXICOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

544 items

☷ Legend

01Approach to the Critical Patient/attcp102

Immediate stabilization

›Resuscitation priorities

›Airway protection trigger

›Ongoing massive hematemesis

›GCS < 13

›Shock triggers

›SBP < 90 mmHg

›MAP < 65 mmHg

›Lactate rising

›Large-bore access

›2 peripheral IVs

›Rapid infuser consideration

›Hemorrhage control bundle

›Mechanical compression for external bleeding

›Tourniquet for uncontrolled extremity bleeding

›Pelvic binder for suspected pelvic fracture

›Massive transfusion activation triggers

›Ongoing hemodynamic instability with suspected major bleed

›Transfusion requirement escalating

Targets and monitoring

›Physiologic targets

›MAP ≥ 65 mmHg

›Hemoglobin trend stabilization

›Platelets ≥ 50 x 10^9/L for major bleeding

›Platelets ≥ 100 x 10^9/L for intracranial bleeding or neurosurgery

›Fibrinogen ≥ 1.5 g/L

›Temperature ≥ 36 C

›Ionized calcium within local reference range

›Monitoring

›Cardiac monitor

›Rate and rhythm for shock physiology

›Frequent vitals

›Every 5-15 minutes during active resuscitation

›Foley consideration

›Urine output trend for shock

›Arterial line trigger

›Refractory shock

›Vasoactive infusion

Anticoagulant identification and reversal triggers

›Anticoagulant exposure classification

›Vitamin K antagonist

›Warfarin

›Direct thrombin inhibitor

›Dabigatran

›Factor Xa inhibitor

›Apixaban

›Rivaroxaban

›Edoxaban

›Betrixaban

›Heparins

›Unfractionated heparin

›Low molecular weight heparin

›Indirect Xa inhibitor

›Fondaparinux

›Major bleeding definition

›Hemodynamic compromise

›Critical site bleeding

›Intracranial

›Intraspinal

›Intraocular with vision threat

›Pericardial

›Airway

›Retroperitoneal

›Overt bleed with significant hemoglobin drop

›Transfusion requirement

›Reversal activation principles

›Life-threatening bleeding

›Immediate reversal pathway

›Major bleeding

›Reversal pathway plus source control

›Non-major bleeding

›Hold agent and supportive care pathway

Source control and consultation triggers

›Source control pathways

›GI bleeding

›GI consult for endoscopy timing

›Intracranial bleeding

›Neurosurgery consult

›Neurocritical care consult

›Trauma

›Trauma team activation

›Pelvic or solid organ bleeding

›Interventional radiology consult

›Hematuria with clot retention

›Urology consult

›Postpartum or uterine bleeding

›Obstetrics consult

›Specialist triggers

›Hematology consult

›Unclear agent

›Refractory coagulopathy

›Suspected superwarfarin exposure

›Poison center or toxicology consult

›Unknown ingestion

›Massive overdose

PITFALLS

›Common errors

›Reversal delay while awaiting definitive imaging in suspected intracranial bleed

›Under-recognition of mixed antithrombotic therapy

›Anticoagulant plus antiplatelet

›Reliance on normal INR to exclude DOAC effect

›Failure to correct hypothermia and hypocalcemia during massive transfusion

PEARLS

›High-yield principles

›Agent-specific reversal when available

›PCC for warfarin-associated major bleeding preferred over plasma in many protocols

›Dabigatran uniquely dialyzable compared with factor Xa inhibitors

›Restart decision individualized after hemostasis and bleed site risk

02History/hx58

Medication and exposure details

›Anticoagulant timeline

›Agent name and formulation

›Indication

›Atrial fibrillation

›VTE treatment

›Mechanical valve

›Prophylaxis

›Last dose time

›Missed doses pattern

›Recent dose changes

›Adherence concerns

›Concomitant medications

›Antiplatelets

›Aspirin

›P2Y12 inhibitors

›NSAIDs

›SSRIs and SNRIs

›Antibiotics interacting with warfarin

›Amiodarone and other CYP interactions

›Renal and hepatic function context

›Chronic kidney disease history

›Cirrhosis history

›Recent dehydration or illness

Bleeding characterization

›Bleeding pattern

›Hematemesis

›Melena

›Hematochezia

›Hematuria

›Epistaxis

›Gingival bleeding

›Heavy menstrual bleeding

›Bruising and hematomas

›Severity markers

›Syncope or presyncope

›Dyspnea

›Chest pain

›New focal neurologic symptoms

›Headache onset and progression

›Trauma and procedures

›Fall or head impact

›Recent surgery

›Recent dental procedure

›Recent lumbar puncture or neuraxial anesthesia

Thrombotic risk context

›High thrombosis-risk conditions

›Mechanical heart valve

›VTE within past 3 months

›Severe thrombophilia history

›Prior cardioembolic stroke

›Baseline stroke or VTE risk tools availability

›CHA2DS2-VASc documented score

›Prior VTE provoked vs unprovoked

Bleeding risk contributors

›Bleeding risk factors

›Prior GI bleed

›Prior intracranial bleed

›Alcohol use disorder

›Falls risk

›Malignancy

›Thrombocytopenia history

03Physical Exam/exam34

Hemodynamics and perfusion

›Perfusion assessment

›Mental status

›Capillary refill

›Skin temperature and mottling

›Volume status clues

›Orthostatic changes when safe

›Jugular venous distension absence or presence

›Shock physiology clues

›Tachycardia

›Narrow pulse pressure

›Cool extremities

Site-focused bleeding exam

›External bleeding search

›Scalp and face

›Oral cavity

›Skin hematomas

›Abdominal and flank

›Tenderness

›Distension

›Cullen sign

›Grey Turner sign

›Rectal exam when indicated

›Melena

›Hematochezia

›Pelvic and vaginal bleeding when indicated

›Active bleeding

›Products of conception consideration in pregnancy

Neurologic

›Intracranial bleeding screen

›GCS

›Pupillary size and reactivity

›Focal deficits

›Seizure activity

PITFALLS

›Missed findings

›Retroperitoneal bleed without overt external signs

›Occult head injury in anticoagulated fall

04Differential Diagnosis/ddx25

Life-threatening etiologies

›Major bleeding syndromes

›Intracranial hemorrhage

›ICD-10 I61.9

›SNOMED intracerebral hemorrhage

›Upper GI bleed

›ICD-10 K92.2

›Ruptured abdominal aortic aneurysm

›ICD-10 I71.4

›Retroperitoneal hemorrhage

›ICD-10 R58

›Hemopericardium with tamponade

›Hemothorax

Coagulopathy contributors and mimics

›Non-anticoagulant coagulopathy

›Liver failure coagulopathy

›DIC

›Uremic platelet dysfunction

›Acquired hemophilia

›Anticoagulant complications

›Warfarin-associated bleeding

›ICD-10 D68.32

›DOAC-associated bleeding

›Heparin-associated bleeding

›Non-bleeding anemia causes

›Hemolysis

›Bone marrow suppression

05Laboratory Tests/lt43

Core labs

›Initial panel

›Complete blood count for bleeding concern

›Hemoglobin trend

›Platelet count

›Electrolytes and renal function

›Creatinine in umol/L

›Liver panel for synthetic function context

›Coagulation screen

›INR

›aPTT

›Type and screen

›Crossmatch trigger for major bleed

›Fibrinogen

›Low value trigger for cryoprecipitate

›VBG or ABG when shock suspected

›pH

›PaCO2 in mmHg

›PaO2 in mmHg

›Lactate in mmol/L

Anticoagulant-specific testing

›Warfarin effect

›INR correlation with intensity

›Bleeding can occur at any INR

›Unfractionated heparin effect

›aPTT interpretation context

›Anti-Xa heparin assay when available

›LMWH effect

›Anti-Xa LMWH assay when available

›Dabigatran effect

›Thrombin time sensitivity

›Dilute thrombin time when available

›Ecarin clotting time when available

›Factor Xa inhibitor effect

›Anti-Xa calibrated assay when available

›INR unreliability for drug effect

Transfusion and resuscitation labs

›Ongoing major hemorrhage monitoring

›Hemoglobin recheck frequency

›Every 2-4 hours during active bleeding

›INR and aPTT reassessment after reversal

›Fibrinogen reassessment after replacement

›Ionized calcium monitoring during massive transfusion

PITFALLS

›Test limitations

›Normal INR does not exclude apixaban or rivaroxaban effect

›aPTT can be normal with clinically relevant DOAC levels

06Diagnostic Tests/dt43

Scoring Systems

›Risk and severity tools

›Major bleeding classification frameworks

›Critical site bleeding as automatic major bleed

›Hemodynamic compromise as major bleed

›GI bleeding risk tools

›Glasgow-Blatchford score for upper GI bleed triage

›Higher score association with need for intervention

›Intracerebral hemorrhage severity

›ICH Score for mortality risk discussion

›Not a sole determinant of goals-of-care decisions

MRI

›MRI indications

›Spinal epidural hematoma concern

›Back pain

›Weakness

›Bowel or bladder dysfunction

›Subacute intracranial bleed evaluation when CT equivocal

›MRI constraints

›Hemodynamic instability as contraindication

›MRI safety screening requirements

›CT head

›Any head trauma on anticoagulant

›Low threshold imaging

›New neurologic deficit

›Severe headache

›CT angiography

›Suspected active arterial bleeding site localization

›GI bleed with hemodynamic instability when endoscopy delayed

›CT abdomen and pelvis

›Suspected retroperitoneal bleed

›Flank pain with falling hemoglobin

Ultrasound (or US)

›POCUS in shock

›Cardiac views for pericardial effusion

›IVC assessment as adjunct

›FAST or eFAST

›Trauma evaluation for free fluid

›Hemothorax evaluation

›Procedural guidance

›Vascular access assistance in shock

Endoscopy and angiography

›Endoscopy considerations

›Upper GI bleed timing coordination with GI

›Airway protection planning for massive hematemesis

›Interventional radiology

›Embolization candidacy for ongoing arterial bleed

07Disposition/dispo26

Level of care

›ICU indications

›Hemodynamic instability

›Ongoing transfusion requirement

›Intracranial hemorrhage

›Need for urgent anticoagulant reversal agent infusion or complex monitoring

›Step-down or ward considerations

›Hemostasis achieved

›Stable hemoglobin trend

›No critical site bleed

›Discharge considerations

›Minor bleeding resolved

›Reliable follow-up within 24-72 hours

›Clear anticoagulant interruption plan

Transfer and specialty destination

›Transfer triggers

›Neurosurgical capability requirement

›Interventional radiology requirement not available

›Endoscopy capability requirement not available

Anticoagulant restart planning

›Restart decision framework

›Critical organ bleed

›Delayed restart typical

›Source not secured

›Delayed restart typical

›High thrombotic risk

›Earlier restart consideration after hemostasis

›Low thrombotic risk

›Discontinuation consideration

08Treatment/t107

General measures

›Immediate actions

›Hold anticoagulant

›Document last dose time estimate

›Local hemostatic measures

›Direct pressure

›Topical hemostatic agents when appropriate

›RBC transfusion strategy

›Symptomatic anemia

›Ongoing hemorrhagic shock

›Platelet transfusion strategy

›Platelets < 50 x 10^9/L with major bleeding

›Platelets < 100 x 10^9/L with intracranial bleeding

›Fibrinogen replacement

›Cryoprecipitate for fibrinogen < 1.5 g/L in major bleed

›Tranexamic acid

›1 g IV over 10 minutes for life-threatening bleeding

›1 g IV over 8 hours continuation in selected protocols

›Calcium replacement during massive transfusion

›Ionized calcium guided dosing

Vitamin K antagonist reversal (warfarin)

›Warfarin reversal pathway

›Four-factor PCC plus vitamin K for major bleeding

›PCC dosing per INR and weight

›INR 2-4

›25 IU/kg

›INR 4-6

›35 IU/kg

›INR > 6

›50 IU/kg

›Maximum dose per local protocol

›Vitamin K 10 mg IV for life-threatening bleeding

›Infusion over 20-60 minutes to reduce reaction risk

›Repeat INR reassessment

›30-60 minutes after PCC

›Additional PCC consideration for persistent elevation with ongoing bleeding

›Plasma use considerations

›PCC unavailable

›Volume overload risk acknowledgment

›Evidence and guideline alignment

›Rapid reversal with PCC favored over plasma in many guidelines for warfarin-associated intracranial hemorrhage (Class I recommendation in ICH-focused guidance)

Direct thrombin inhibitor reversal (dabigatran)

›Dabigatran pathway

›Idarucizumab

›5 g IV total

›2.5 g IV x 2 doses

›Back-to-back administration acceptable

›Rebound anticoagulant effect risk

›Consider repeat labs and clinical reassessment

›Activated charcoal

›Recent ingestion window

›Within 2 hours typical consideration

›Airway protected requirement if altered mental status

›Hemodialysis

›Life-threatening bleeding with renal failure or massive exposure

›Significant dabigatran removal compared with factor Xa inhibitors

›Evidence and guideline alignment

›Specific antidote use supported in intracranial hemorrhage guidance (Class I recommendation in ICH-focused guidance)

Factor Xa inhibitor reversal (apixaban, rivaroxaban, edoxaban, betrixaban)

›Factor Xa inhibitor pathway

›Andexanet alfa when available and appropriate

›Dosing per agent and last dose timing per institutional protocol

›Thrombotic risk counseling and monitoring

›Four-factor PCC alternative

›50 IU/kg commonly used in many institutional pathways

›Maximum dose per local protocol

›Activated charcoal

›Recent ingestion window

›Within 2 hours typical consideration

›Airway protected requirement if altered mental status

›Evidence and guideline alignment

›Andexanet alfa supported for factor Xa inhibitor reversal in ICH-focused guidance (Class IIa in many summaries)

›PCC used when andexanet unavailable or unsuitable in many pathways

Unfractionated heparin reversal

›UFH pathway

›Protamine

›1 mg per 100 units heparin given in previous 2-3 hours

›Maximum 50 mg per dose in many protocols

›Slow IV administration to reduce hypotension risk

›Monitoring

›aPTT or anti-Xa reassessment after protamine

›Evidence alignment

›Protamine use suggested for life-threatening bleeding in heparin therapy guidance

Low molecular weight heparin reversal (enoxaparin and similar)

›LMWH pathway

›Protamine partial reversal

›Within 8 hours of LMWH dose

›1 mg protamine per 1 mg enoxaparin equivalent

›8-12 hours after dose

›0.5 mg protamine per 1 mg enoxaparin equivalent

›Second dose consideration

›0.5 mg protamine per 1 mg enoxaparin equivalent if ongoing bleeding

›Anti-Xa monitoring limitations

›Clinical hemostasis as primary endpoint

Fondaparinux-associated bleeding

›Fondaparinux pathway

›No specific antidote widely available

›PCC consideration in life-threatening bleeding per institutional protocol

›Supportive care emphasis

›Source control priority

Adjuncts and special therapies

›Desmopressin consideration

›Suspected uremic platelet dysfunction

›Antiplatelet co-exposure with critical bleeding site

›Antifibrinolytic coordination

›Trauma protocols alignment when trauma suspected

›Thrombosis mitigation after reversal

›Mechanical VTE prophylaxis when safe

›Restart anticoagulant planning after hemostasis

Evidence framework summary

›Guideline concepts

›ACC consensus pathway focus

›Bleeding severity stratification

›Temporary interruption

›Reversal for life-threatening bleeding

›Restart assessment after control

09Special Populations/sp30

Pregnancy

›Pregnancy considerations

›Physiologic hypercoagulability context

›High thrombosis risk if anticoagulant withheld

›Preferred anticoagulants in pregnancy context

›LMWH common outpatient agent

›Reversal and consultation

›Obstetrics involvement for uterine or postpartum bleeding

›Neuraxial anesthesia timing awareness

›Imaging selection

›CT when life-threatening hemorrhage suspected

›MRI for spinal epidural hematoma concern when stable

Geriatric

›Older adult considerations

›Falls and head trauma threshold

›Low threshold CT head

›Renal clearance changes

›DOAC accumulation risk

›Polypharmacy interactions

›Warfarin interaction risk

›Transfusion tolerance considerations

›Heart failure risk with plasma

Pediatrics

›Pediatric considerations

›Weight-based dosing requirement

›PCC and protamine dosing verification

›Anticoagulant exposure context

›Congenital heart disease

›ECMO or ventricular assist device

›Specialty consultation

›Pediatric hematology involvement early

›Antidote availability

›Institution-specific pediatric stocking policies

10Background/b30

Epidemiology

›Frequency and context

›Anticoagulant use prevalence rising with atrial fibrillation and VTE indications

›Major bleeding risk varies by agent and patient comorbidity

›Intracranial hemorrhage as high-mortality anticoagulant complication

Pathophysiology

›Mechanisms

›Warfarin effect

›Reduced vitamin K dependent clotting factors

›Dabigatran effect

›Direct thrombin inhibition

›Factor Xa inhibitor effect

›Inhibition of factor Xa in coagulation cascade

›Heparin effect

›Antithrombin-mediated inhibition of thrombin and factor Xa

›Hemorrhage physiology

›Coagulopathy plus local vascular injury as common pathway

›Shock triad

›Hypothermia

›Acidosis

›Coagulopathy

Therapeutic Considerations

›Reversal strategy principles

›Agent-specific antidote preference when available

›PCC rapid factor replacement for warfarin-associated major bleeding

›Vitamin K for sustained warfarin reversal

›Dialysis utility mainly for dabigatran

›Risk tradeoffs

›Thrombotic event risk after reversal agents

›Restart timing individualized by bleed site and indication

›Evidence framing

›Intracranial hemorrhage guidance emphasizes rapid reversal to limit hematoma expansion

›ACC pathway emphasizes severity-based reversal and structured restart assessment

11Patient Discharge Instructions/pdi26

copy discharge instructions

›Discharge guidance

›Anticoagulant plan

›Hold or restart date and time written clearly

›Do not double-dose if a dose was missed unless instructed

›Medication safety

›Avoid NSAIDs unless clinician-approved

›Avoid new over-the-counter supplements without checking interactions

›Alcohol moderation

›Follow-up

›Primary care or anticoagulation clinic within 24-72 hours

›INR recheck timing if on warfarin

›Renal function recheck timing if on DOAC and recent illness

›Return to ED immediately for

›Any head injury or fall

›Severe headache

›New weakness, numbness, speech change, confusion

›Fainting or near-fainting

›Vomiting blood

›Black or bloody stool

›Blood in urine with clots

›Heavy vaginal bleeding

›Shortness of breath or chest pain

›Bleeding prevention

›Soft toothbrush and gentle flossing

›Electric razor

›Avoid high-risk contact activities until cleared

12References/r20

Clinical guidelines and consensus

›Guideline sources

›AHA/ASA guideline for spontaneous intracerebral hemorrhage

›Warfarin-associated ICH rapid reversal recommendations

›Dabigatran reversal with idarucizumab recommendations

›Factor Xa inhibitor reversal with andexanet alfa considerations

›ACC expert consensus decision pathway for bleeding on oral anticoagulants

›Bleeding severity stratification

›Reversal agent decision support

›Restart anticoagulation considerations

›Neurocritical Care Society and Society of Critical Care Medicine guideline for antithrombotic reversal in intracranial hemorrhage

›PCC preference over plasma for VKA-associated ICH in many recommendations

›American Society of Hematology guidelines on anticoagulation therapy

›Protamine suggestions for life-threatening bleeding on UFH or LMWH

Evidence-based reviews and tools

›Supporting evidence categories

›Comparative studies of PCC versus plasma for rapid INR correction

›Antidote trials and post-marketing safety for idarucizumab and andexanet alfa

›GI bleeding risk stratification tools

›Glasgow-Blatchford score validation studies

›Intracerebral hemorrhage severity prediction tools

›ICH Score derivation and validation studies

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.